North American Management Corp purchased a new stake in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, Holdings Channel reports. The firm purchased 800 shares of the medical instruments supplier’s stock, valued at approximately $253,000.

Several other hedge funds have also recently added to or reduced their stakes in BCR. Cribstone Capital Management LLC bought a new position in shares of C.R. Bard during the first quarter valued at approximately $130,000. Contravisory Investment Management Inc. raised its position in shares of C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 426 shares during the last quarter. Whittier Trust Co. raised its position in shares of C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares during the last quarter. ClariVest Asset Management LLC bought a new position in shares of C.R. Bard during the first quarter valued at approximately $148,000. Finally, SRS Capital Advisors Inc. raised its position in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the last quarter. 87.63% of the stock is owned by institutional investors and hedge funds.

Shares of C.R. Bard, Inc. (NYSE BCR) traded down 0.12% during midday trading on Monday, hitting $319.65. 170,760 shares of the stock were exchanged. The company has a market cap of $23.15 billion, a price-to-earnings ratio of 40.68 and a beta of 0.59. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $320.37. The firm has a 50 day moving average of $311.80 and a 200-day moving average of $264.06.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The firm had revenue of $938.80 million for the quarter, compared to analyst estimates of $916.15 million. During the same quarter in the prior year, the company posted $2.34 earnings per share. C.R. Bard’s quarterly revenue was up 7.5% on a year-over-year basis. Equities analysts expect that C.R. Bard, Inc. will post $11.78 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Thursday, July 20th. C.R. Bard’s dividend payout ratio is presently 13.21%.

WARNING: “North American Management Corp Buys New Stake in C.R. Bard, Inc. (NYSE:BCR)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/07/17/north-american-management-corp-buys-new-stake-in-c-r-bard-inc-nysebcr.html.

Several brokerages recently commented on BCR. BMO Capital Markets lowered shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price objective for the company. in a research report on Tuesday, April 25th. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective for the company in a research report on Tuesday, June 13th. Morgan Stanley lowered shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research report on Monday, April 24th. Cowen and Company increased their price objective on shares of C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a research report on Monday, April 24th. Finally, Jefferies Group LLC increased their price objective on shares of C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a research report on Monday, April 24th. Eleven analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the stock. C.R. Bard currently has an average rating of “Hold” and a consensus target price of $271.31.

In related news, VP Frank Lupisella, Jr. sold 3,622 shares of the company’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the transaction, the vice president now owns 10,139 shares of the company’s stock, valued at $3,082,256. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.80% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.